Deciphering the mechanism of Chaihu Shugan San in the treatment of nonalcoholic steatohepatitis using network pharmacology and molecular docking
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yi Ren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Molecular Docking Simulation, Diet, High-Fat, Sirtuin 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Gene Ontology.
Abstract (Originalsprache)
Objectives
In China, there is a long history and rich clinical experience in treating nonalcoholic steatohepatitis (NASH) with traditional Chinese herbal medicines, including Chai Hu Shu Gan San. This study aims to investigate the potential regulatory effects of Chaihu Shugan San (CSS) on liver lipid metabolism and inflammatory damage in mice with experimental nonalcoholic steatohepatitis (NASH) induced by a choline-deficient high-fat diet (CDHFD). Utilizing network pharmacology, we systematically explore the mechanisms of action and therapeutic potential of CSS against NASH.
Methods
Potential targets in CSS and targets for NASH were identified using online databases. Functional enrichment and protein–protein interaction analyses were conducted to identify hub-targeted genes and elucidate the underlying molecular mechanisms. The affinities of active compounds in CSS with hub-targeted genes were evaluated using molecular docking. Finally, hub-targeted genes were validated through real-time polymerase chain reaction, western blotting, and immunofluorescence in choline-deficient high-fat diet mice, both with and without CSS treatment. Key findings CSS reduces serum ALT and AST levels in NASH mice(P < 0.05) and ameliorates ballooning degeneration in the livers of NASH mice, thereby lowering the NAS score(P < 0.05). Including naringenin, high-performance liquid chromatography/mass spectrometrys identified 12 chromatographic peaks. Based on network pharmacology analysis, CSS contains a total of 103 active compounds and 877 target genes. Transferase activity represents a potential mechanism for therapeutic intervention of CSS in NASH. The transcriptional levels and protein expression of the SIRT1 gene in NASH mice are significantly increased by CSS (P < 0.05).
Conclusions
Naringenin is probable active compound in CSS and SIRT1 is the hub gene by which CSS is involved in NASH treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Clinical Center for Metabolic Associated Fatty Liver Disease, Capital Medical University, Beijing 100050, China.
ORCID-Profile: Yi Ren, Jingjie Zhao
Förderung
- Gene Ontology
Zitieren
APA
Ren, Y., Xiao, K., Lu, Y., Chen, W., Li, L., & Zhao, J. (2024). Deciphering the mechanism of Chaihu Shugan San in the treatment of nonalcoholic steatohepatitis using network pharmacology and molecular docking. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae103
Vancouver
Ren Y, Xiao K, Lu Y, Chen W, Li L, Zhao J. Deciphering the mechanism of Chaihu Shugan San in the treatment of nonalcoholic steatohepatitis using network pharmacology and molecular docking. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae103
BibTeX
@article{Ren2024,
author = {Ren, Yi and Xiao, Kaihui and Lu, Yujia and Chen, Wei and Li, Li and Zhao, Jingjie},
title = {Deciphering the mechanism of Chaihu Shugan San in the treatment of nonalcoholic steatohepatitis using network pharmacology and molecular docking},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae103}
}
EUVIMED